Key Portfolio Moves: Cathie Wood’s ARK Invest ETFs made significant purchases on October 20, 2025, focusing on diagnostics and health-tech, including a $5.56 million investment in Exact Sciences and additional stakes in Illumina, Qualcomm, and BYD Co.
Sell-Offs and Reductions: ARK also reduced its holdings, notably selling $8.13 million worth of Guardant Health and $8.04 million of Kratos Defense & Security Solutions, continuing a trend of decreasing exposure to precision oncology and defense sectors.
EXAS
$101.495+Infinity%1D
Analyst Views on EXAS
Wall Street analysts forecast EXAS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 95.50 USD with a low forecast of 50.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Analyst Rating
Wall Street analysts forecast EXAS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 95.50 USD with a low forecast of 50.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
17 Hold
0 Sell
Hold
Current: 101.500
Low
50.00
Averages
95.50
High
105.00
Current: 101.500
Low
50.00
Averages
95.50
High
105.00
Stifel
Buy
to
Hold
downgrade
$80 -> $105
2025-11-28
Reason
Stifel
Price Target
$80 -> $105
2025-11-28
downgrade
Buy
to
Hold
Reason
Stifel downgraded Exact Sciences (EXAS) to Hold from Buy with a price target of $105, up from $80, after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share.
Piper Sandler
David Westenberg
Overweight -> Neutral
downgrade
$105
2025-11-24
Reason
Piper Sandler
David Westenberg
Price Target
$105
2025-11-24
downgrade
Overweight -> Neutral
Reason
Piper Sandler analyst David Westenberg downgraded Exact Sciences (EXAS) to Neutral from Overweight with a $105 price target after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share.
Canaccord
Buy
to
Hold
downgrade
$85 -> $105
2025-11-24
Reason
Canaccord
Price Target
$85 -> $105
2025-11-24
downgrade
Buy
to
Hold
Reason
Canaccord downgraded Exact Sciences (EXAS) to Hold from Buy with a price target of $105, up from $85, after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share.
TD Cowen
TD Cowen
Buy
to
Hold
downgrade
$105
2025-11-24
Reason
TD Cowen
TD Cowen
Price Target
$105
2025-11-24
downgrade
Buy
to
Hold
Reason
TD Cowen downgraded Exact Sciences (EXAS) to Hold from Buy with a $105 price target after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share.
About EXAS
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
